Clovis Oncology Inc CLVS:NASDAQ

Last Price$1.80NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.09(5.26%)
Bid (Size)$1.80 (38)
Ask (Size)$1.83 (127)
Day Low / High$1.63 - 1.95
Volume12.5 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022


Clovis Oncology Inc ( NASDAQ )

Price: $1.80
Change: +0.09 (5.26%)
Volume: 12.5 M
4:00PM ET 6/30/2022

Sutro Biopharma Inc ( NASDAQ )

Price: $5.21
Change: -0.03 (0.57%)
Volume: 1.6 M
4:00PM ET 6/30/2022

Provention Bio Inc ( NASDAQ )

Price: $4.00
Change: +0.09 (2.30%)
Volume: 594.3 K
4:00PM ET 6/30/2022


Price: $22.28
Change: +1.83 (8.95%)
Volume: 44.8 K
4:00PM ET 6/30/2022

EyePoint Pharmaceuticals Inc ( NASDAQ )

Price: $7.87
Change: +0.04 (0.51%)
Volume: 214.8 K
4:00PM ET 6/30/2022

Read more news Recent News

Top Premarket Gainers
8:18AM ET 6/14/2022 MT Newswires

Kaival Brands (KAVL) shares soared 52% in premarket trading Tuesday on a deal with Philip Morris (PM) for the development and distribution of electronic...

-- Earnings Flash (CLVS) CLOVIS ONCOLOGY Reports Q1 Loss $-0.44, vs. Street Est of $-0.49
8:06AM ET 5/04/2022 MT Newswires


Sector Update: Health Care Stocks Sidestep Steeper Thursday Market Losses
4:07PM ET 3/31/2022 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index slipping 0.6% and the SPDR Health Care Select Sector ETF (XLV)...

Sector Update: Health Care Stocks Mixed in Thursday Trading
2:00PM ET 3/31/2022 MT Newswires

Health care stocks were narrowly mixed this afternoon, with the NYSE Health Care Index slipping less than 0.1% while the SPDR Health Care Select Sector ETF...

View all Commentary and Analysis

ImmunoGen: An Inflection Point In Growth
4:16PM ET 5/17/2022 Seeking Alpha

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2022 Results - Earnings Call Transcript
12:30PM ET 5/04/2022 Seeking Alpha

Myovant: Poised To Overcome Regulatory Issues
12:16PM ET 4/26/2022 Seeking Alpha

Clovis: Shifting Toward Nuclear Medicine
12:33PM ET 4/25/2022 Seeking Alpha

Company Profile

Business DescriptionClovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. View company web site for more details
Address5500 Flatiron Parkway
Boulder, Colorado 80301
Number of Employees468
Recent SEC Filing06/28/2022DEFA14A
President, Chief Executive Officer & DirectorPatrick J. Mahaffy
Chief Financial Officer & Executive Vice PresidentDaniel W. Muehl
Chief Medical Officer & Executive VP-ClinicalLindsey Rolfe
Chief Scientific Officer & Executive VPThomas Fuglsang Harding

Company Highlights

Price Open$1.68
Previous Close$1.71
52 Week Range$0.58 - 5.92
Market Capitalization$259.0 M
Shares Outstanding143.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.06
Beta vs. S&P 500N/A
Revenue$95.4 M
Net Profit Margin-178.28%
Return on Equity101.88%

Analyst Ratings as of 05/06/2022

Consensus RecommendationConsensus Icon
Powered by Factset